Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Shares Soar on Speculation of Lawsuit Settlement With Agilent

NEW YORK – Shares of Twist Bioscience rose 12 percent in afternoon trading on the Nasdaq on speculation that the synthetic DNA manufacturer is close to settling a trade secrets lawsuit filed by Agilent Technologies.

The San Francisco-based company's stock opened Thursday trading at $26.83 and the shares rose sharply in mid-afternoon trade to $30.11.

In a note to investors, Cowen Analyst Doug Schenkel wrote that the competitors "could be close" to settling an intellectual property lawsuit Agilent filed in 2016 against Twist, CEO and Cofounder Emily Leproust, and several other individuals. "Developments this afternoon ... are consistent with what you might expect if a settlement were imminent," he wrote.

According to the court docket, a hearing in the Santa Clara (California) Superior Court scheduled for Friday afternoon was cancelled. A trial set to begin Feb. 24 also appears to be cancelled.

"Our [legal] consultant indicated that while the court was not at liberty to confirm, these developments would often suggest that a settlement is close," Schenkel wrote.

Neither firm immediately responded to request for comment.

Leproust, a former Agilent employee, founded Twist in 2013. The Agilent lawsuit alleged Leproust and others misappropriated Agilent technology and that Leproust violated a contractual obligation to refrain from recruiting former colleagues for a period of two years. Agilent also alleged that Leproust actually founded Twist in 2011 while still employed by the firm.

Twist is scheduled to report its first quarter results for fiscal year 2020 after the close of the market on Thursday. The firm has previously said it believes the claims are "meritless" and that it would "defend itself vigorously."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.